A

nd so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Once again, our agenda is rather modest. Beyond a visit to the Pharmalot ancestors, we plan to catch up on reading, chores, and naps. And what about you? This may be a good time to enjoy the great outdoors. You could plan a summer getaway. Or simply plan the rest of your life. Well, whatever you do, have a grand time. But be safe. And if this applies, remember to call Dad. See you soon …

After a prolonged row, the U.K.’s National Institute for Health and Care Excellence and Roche have finally struck a deal for routine use of the Kadcyla breast cancer drug on the National Health Service, The Guardian writes. Details were not disclosed, but Roche will offer a discount. Until now, the drug has only been covered by the Cancer Drugs Fund, which finances drugs not routinely paid for on the NHS.

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Leave a Comment

Please enter your name.
Please enter a comment.

Recommended Stories

Sign up for our biotech newsletter, The Readout

A guide to what’s new in biotech — delivered straight to your inbox every weekday morning.